


What is claimed is:


1. A method of reducing the viability of leukemia cells in a mammal sensitive to a 1-(R) compound of formula (II):



wherein R¹ is lower alkyl, lower alkenyl, lower alkynyl, lower cycloalkyl, phenyl or benzyl, R², R³, R⁴ and R⁵ are the same or different and are each hydrogen or lower alkyl; R⁶ is hydrogen, lower alkyl, hydroxy, lower alkoxy, benzyloxy, lower alkanoyloxy, nitro or halo, R⁷ is hydrogen, lower alkyl or lower alkenyl; X is oxy; Y is carbonyl or (C₁-C₃)alkyl(CO), wherein each alkyl is substituted with 0-2 (C₁-C₄) alkyl, and Z is hydroxy, lower alkoxy, amino, lower alkylamino, di(lower)alkylamino or phenylamino;

comprising administering from about 50 mg to about 5000 mg of the (R)-compound of formula (II); or a salt thereof to a human cancer patient afflicted with a leukemia.

2. A method of increasing the susceptibility of leukemia cells in a mammal to a chemotherapeutic agent comprising contacting the cells with from about 50 mg to about 5000 mg of a compound of formula (II):



wherein R¹ is lower alkyl, lower alkenyl, lower alkynyl, lower cycloalkyl, phenyl or benzyl, R², R³, R⁴ and R⁵ are the same or different and are each

hydrogen or lower alkyl; R⁶ is hydrogen, lower alkyl, hydroxy, lower alkoxy, benzyloxy, lower alkanoyloxy, nitro or halo, R⁷ is hydrogen, lower alkyl or lower alkenyl; X is oxy; Y is carbonyl or (C₁-C₃)alkyl(CO), wherein each alkyl is substituted with 0-2 (C₁-C₄) alkyl, and Z is hydroxy, lower alkoxy, amino, lower alkylamino, di(lower)alkylamino or phenylamino; or a pharmaceutically acceptable salt thereof.

3. The method of claim 1 wherein concentration of the compound of formula (II) about 100 mg to about 2500 mg
4. The method of claim 2 wherein concentration of the compound of formula (II) about 100 mg to about 2500 mg
5. The method of claim 1 wherein the compound of formula (II) is administered in a single dose
6. The method of claim 2 wherein the compound of formula (II) is administered in a single dose
7. The method of claim 1 wherein the compound of formula (II) is administered in divided doses
8. The method of claim 2 wherein the compound of formula (II) is administered in divided doses
9. The method of claim 1 wherein the concentration of the compound of formula (II) is from about 200 μ M to about 400 μ M.

10. The method of claim 1 wherein the concentration of the compound of formula (II) is from about 200 μ M to about 400 μ M.
11. The method of claim 1 wherein the leukemia is chronic lymphocytic leukemia.
12. The method of claim 2 wherein the leukemia is chronic lymphocytic leukemia.
13. The method of claim 1 wherein the a mammal is a human.
14. The method of claim 2 wherein the a mammal is a human.
15. The method of claim 14 wherein the mammal is undergoing treatment with a chemotherapeutic agent.
16. The method of claim 1 wherein the compound of formula (II) or the salt thereof is administered orally.
17. The method of claim 2 wherein the compound of formula (II) or the salt thereof is administered orally.
18. The method of claim 1 wherein the compound of formula (II) is R(-)-etodolac.
19. The method of claim 2 wherein the compound of formula (II) is R(-)-etodolac.

20. The method of claim 15 wherein compound of formula (II) is administered in combination with the chemotherapeutic agent.